Digest Network Come funziona
Network
/
Società
Ja
Non verificato

Janux Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaOncologiaSaluteScienza

27 comunicati stampa

Guarda tutti i comunicati
07/05/2026
Mercato azionario
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
Fonte
Janux Therapeutics
Emittente
Business Wire
1.00
0
16/04/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
Fonte
Janux Therapeutics
Emittente
Business Wire
1.00
0
01/04/2026
Mercato del lavoro
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment
Fonte
Janux Therapeutics
Emittente
Business Wire
1.00
0
26/02/2026
Mercato del lavoro
Mercato azionario
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Fonte
Janux Therapeutics
Emittente
Business Wire
1.00
0
17/02/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
Fonte
Janux Therapeutics
Emittente
Business Wire
1.00
0
26/01/2026
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Mercato del lavoro
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer
Fonte
Janux Therapeutics
Emittente
Business Wire
1.00
0
22/01/2026
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Industria
Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors
Fonte
Janux Therapeutics
Emittente
Business Wire
1.00
0
23/12/2025
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study
Fonte
Janux Therapeutics
Emittente
Business Wire
1.00
0
01/12/2025
Web e Social Network
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC
Fonte
Janux Therapeutics
Emittente
Business Wire
1.00
0
24/11/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Industria
Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC
Fonte
Janux Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0